Drug companies are bracing themselves for European Union probes into anti-competitive behaviour after the publication this week of an intensive inquiry into the pharmaceuticals sector.

Neelie Kroes, EU competition commissioner, is poised to release interim findings from an investigation launched in January to examine practices by innovator and generic drug companies that she suggested could be slowing the launch of new patented and cheaper generic medicines.